logo
logo

Meliora Therapeutics Raises $11M Seed Financing To Develop First Mechanism Of Action Atlas In Oncology

Sep 29, 2022•almost 3 years ago

Amount Raised

$11 Million

Round Type

seed

San FranciscoBiotechnology

Description

Meliora Therapeutics, a biotech company pioneering a machine learning-driven platform to decipher oncology drugs’ true mechanisms-of-action, announced today the close of an $11M seed financing round led by HOF Capital and ZhenFund, with participation from Obvious Ventures, Village Global, BrightEdge (the impact investment arm of the American Cancer Society), Pebblebed (fund of Keith Adams, former Chief Architect at Slack), Axial, Olive Capital, and prominent individual investors Michael Polansky (co-founder of Parker Institute for Cancer Immunotherapy and ArsenalBio), Wes Sterman (founding investor for Gilead), and others.

Company Information

Company

Meliora Therapeutics

Location

San Francisco, California, United States

About

Meliora is reimagining modern cancer drug development by putting genomics and cutting-edge computational approaches as first class principles of product development. The company has developed "molecular fingerprints" for tens of thousands of compounds in order to build an inference engine that identifies risk-adjusted small molecule compound and target mechanism of action (MOA) pairs. This proprietary discovery engine converts the existing world of optimized chemistry into an asset generating flywheel with high potential for clinical success. The company is headquartered in Menlo Park, CA. For more information, visit www.melioratx.com.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech